Brits balk at high price of Roche cancer drug

The British National Institute for Health and Clinical Excellence (NICE) decides that Roche's (OTCQX:RHHBY) breast cancer drug Kadcyla (ado-trastuzumab emtansine) is too expensive for routine use by the National Health Service despite the company's offering of a discount.

NICE determines what drugs will be used by the NHS. It originally called for the company to reduce the price back in April. Kadcyla is a treatment for women with refractory metastatic HER2-positive breast cancer where surgical resection is not an option. It costs almost 91,000 pounds ($152,800) for a full course of treatment.

Roche says it has offered a significant discount and will appeal NICE's decision.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs